2026 Q2 -tulosraportti
66 päivää sitten
‧58 min
5,00 DKK/osake
Viimeisin osinko
5,63%Tuotto/v
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 18.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 12.5. | ||
2026 Q1 -tulosraportti 6.2. | ||
Vuosittainen yhtiökokous 2025 4.12.2025 | ||
2025 Q4 -tulosraportti 4.11.2025 | ||
2025 Q3 -tulosraportti 19.8.2025 |
Asiakkaat katsoivat myös
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
·36 min sittenLittle RED lamp ....Look at a weekly trend channel since price 1000 ...840...etc etc the entire downtrend channel .....it is now at resistance at 425/430 .....Was last tested at 590 after rally and then we got the whole trip down. I would actually like to enter after this nice SHS 425 / 370 /425 = 490 target ...but will probably see if we can really break the curse in the downtrend ...if this is the case I am clearly back towards 490 0g 550 initially otherwise it's 390 again.....
·7 t sittenDo you think it's turning around now and one should buy in, or should one wait and see? Is there any explanation for why it has risen lately?see comment about long term trendline precisely at 425/430....if break of weekly close...reversal ... if rejected, risk 380/90 again....pure technicals .
·15 t sittenWhy has Coloplast's Kerecis acquisition faced challenges? That's what investors are keeping an eye on... Coloplast acquired Kerecis in 2023 to strengthen its position in advanced wound care with the expectation that the company could become a long-term growth engine. What changed? Medicare (USA) changed the rules for reimbursement of skin substitutes used in American outpatient wound clinics. Changes in coverage and payment made healthcare providers more cautious about using advanced skin substitutes. The reimbursement changes affected the entire market for skin substitutes – not just Kerecis. Consequence for Coloplast Kerecis experienced a significant sales decline in the American outpatient market. Coloplast lowered its growth expectations for Kerecis and recognized a goodwill impairment of 3.0 mia. kr. Management has highlighted that the underlying technology remains strong, and that sales to hospitals (inpatient) continue to show healthy growth. What should investors keep an eye on to see if the acquisition creates growth again? Whether Kerecis again begins to deliver accelerating revenue growth in the upcoming quarterly results. Continued growth in the hospital market, so that dependence on outpatient wound clinics is reduced. International growth that reduces dependence on the American reimbursement system. New clinical results and increased physician acceptance that can support broader use of Kerecis products. Improved profitability and signs that Kerecis can become a significant contributor to Coloplast's earnings. Conclusion: The challenge primarily concerns reimbursement and market access and not the underlying technology based on fish skin. The success of the acquisition depends on whether Coloplast can adapt the commercial model, expand into new sales channels, and rebuild sustainable growth... or also - that the new restrictions in the USA (perhaps) will be eased, which would increase demand for the product again... that would give the Coloplast share tailwind going forward.
Their technology of using fish skin in wound care is very exciting. The timing of the acquisition has probably just been unfortunate with the change in reimbursement rules through Medicare. See also: https://www.coloplast.com/wound-tissue-repair/?srsltid=AfmBOor2B382L25KTUP7nN7sVYYPUWWcmyYUOr7RtjD0dDqIrWehBm8j Furthermore, I think that the Danish medico stocks are attractively priced at present despite price pressure, reduced reimbursement, and geopolitical unrest.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q2 -tulosraportti
66 päivää sitten
‧58 min
5,00 DKK/osake
Viimeisin osinko
5,63%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·36 min sittenLittle RED lamp ....Look at a weekly trend channel since price 1000 ...840...etc etc the entire downtrend channel .....it is now at resistance at 425/430 .....Was last tested at 590 after rally and then we got the whole trip down. I would actually like to enter after this nice SHS 425 / 370 /425 = 490 target ...but will probably see if we can really break the curse in the downtrend ...if this is the case I am clearly back towards 490 0g 550 initially otherwise it's 390 again.....
- ·7 t sittenDo you think it's turning around now and one should buy in, or should one wait and see? Is there any explanation for why it has risen lately?see comment about long term trendline precisely at 425/430....if break of weekly close...reversal ... if rejected, risk 380/90 again....pure technicals .
- ·15 t sittenWhy has Coloplast's Kerecis acquisition faced challenges? That's what investors are keeping an eye on... Coloplast acquired Kerecis in 2023 to strengthen its position in advanced wound care with the expectation that the company could become a long-term growth engine. What changed? Medicare (USA) changed the rules for reimbursement of skin substitutes used in American outpatient wound clinics. Changes in coverage and payment made healthcare providers more cautious about using advanced skin substitutes. The reimbursement changes affected the entire market for skin substitutes – not just Kerecis. Consequence for Coloplast Kerecis experienced a significant sales decline in the American outpatient market. Coloplast lowered its growth expectations for Kerecis and recognized a goodwill impairment of 3.0 mia. kr. Management has highlighted that the underlying technology remains strong, and that sales to hospitals (inpatient) continue to show healthy growth. What should investors keep an eye on to see if the acquisition creates growth again? Whether Kerecis again begins to deliver accelerating revenue growth in the upcoming quarterly results. Continued growth in the hospital market, so that dependence on outpatient wound clinics is reduced. International growth that reduces dependence on the American reimbursement system. New clinical results and increased physician acceptance that can support broader use of Kerecis products. Improved profitability and signs that Kerecis can become a significant contributor to Coloplast's earnings. Conclusion: The challenge primarily concerns reimbursement and market access and not the underlying technology based on fish skin. The success of the acquisition depends on whether Coloplast can adapt the commercial model, expand into new sales channels, and rebuild sustainable growth... or also - that the new restrictions in the USA (perhaps) will be eased, which would increase demand for the product again... that would give the Coloplast share tailwind going forward.Their technology of using fish skin in wound care is very exciting. The timing of the acquisition has probably just been unfortunate with the change in reimbursement rules through Medicare. See also: https://www.coloplast.com/wound-tissue-repair/?srsltid=AfmBOor2B382L25KTUP7nN7sVYYPUWWcmyYUOr7RtjD0dDqIrWehBm8j Furthermore, I think that the Danish medico stocks are attractively priced at present despite price pressure, reduced reimbursement, and geopolitical unrest.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 18.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 12.5. | ||
2026 Q1 -tulosraportti 6.2. | ||
Vuosittainen yhtiökokous 2025 4.12.2025 | ||
2025 Q4 -tulosraportti 4.11.2025 | ||
2025 Q3 -tulosraportti 19.8.2025 |
2026 Q2 -tulosraportti
66 päivää sitten
‧58 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q3 -tulosraportti 18.8. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q2 -tulosraportti 12.5. | ||
2026 Q1 -tulosraportti 6.2. | ||
Vuosittainen yhtiökokous 2025 4.12.2025 | ||
2025 Q4 -tulosraportti 4.11.2025 | ||
2025 Q3 -tulosraportti 19.8.2025 |
5,00 DKK/osake
Viimeisin osinko
5,63%Tuotto/v
Foorumi
Liity keskusteluun Nordnet Socialissa
Kirjaudu
- ·36 min sittenLittle RED lamp ....Look at a weekly trend channel since price 1000 ...840...etc etc the entire downtrend channel .....it is now at resistance at 425/430 .....Was last tested at 590 after rally and then we got the whole trip down. I would actually like to enter after this nice SHS 425 / 370 /425 = 490 target ...but will probably see if we can really break the curse in the downtrend ...if this is the case I am clearly back towards 490 0g 550 initially otherwise it's 390 again.....
- ·7 t sittenDo you think it's turning around now and one should buy in, or should one wait and see? Is there any explanation for why it has risen lately?see comment about long term trendline precisely at 425/430....if break of weekly close...reversal ... if rejected, risk 380/90 again....pure technicals .
- ·15 t sittenWhy has Coloplast's Kerecis acquisition faced challenges? That's what investors are keeping an eye on... Coloplast acquired Kerecis in 2023 to strengthen its position in advanced wound care with the expectation that the company could become a long-term growth engine. What changed? Medicare (USA) changed the rules for reimbursement of skin substitutes used in American outpatient wound clinics. Changes in coverage and payment made healthcare providers more cautious about using advanced skin substitutes. The reimbursement changes affected the entire market for skin substitutes – not just Kerecis. Consequence for Coloplast Kerecis experienced a significant sales decline in the American outpatient market. Coloplast lowered its growth expectations for Kerecis and recognized a goodwill impairment of 3.0 mia. kr. Management has highlighted that the underlying technology remains strong, and that sales to hospitals (inpatient) continue to show healthy growth. What should investors keep an eye on to see if the acquisition creates growth again? Whether Kerecis again begins to deliver accelerating revenue growth in the upcoming quarterly results. Continued growth in the hospital market, so that dependence on outpatient wound clinics is reduced. International growth that reduces dependence on the American reimbursement system. New clinical results and increased physician acceptance that can support broader use of Kerecis products. Improved profitability and signs that Kerecis can become a significant contributor to Coloplast's earnings. Conclusion: The challenge primarily concerns reimbursement and market access and not the underlying technology based on fish skin. The success of the acquisition depends on whether Coloplast can adapt the commercial model, expand into new sales channels, and rebuild sustainable growth... or also - that the new restrictions in the USA (perhaps) will be eased, which would increase demand for the product again... that would give the Coloplast share tailwind going forward.Their technology of using fish skin in wound care is very exciting. The timing of the acquisition has probably just been unfortunate with the change in reimbursement rules through Medicare. See also: https://www.coloplast.com/wound-tissue-repair/?srsltid=AfmBOor2B382L25KTUP7nN7sVYYPUWWcmyYUOr7RtjD0dDqIrWehBm8j Furthermore, I think that the Danish medico stocks are attractively priced at present despite price pressure, reduced reimbursement, and geopolitical unrest.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Nordnet Socialin käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Ei dataa
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Huomioi, että vaikka osakkeisiin säästäminen on pitkällä aikavälillä tuottanut hyvin, tulevasta tuotosta ei ole takeita. On olemassa riski, että et saa sijoittamiasi varoja takaisin.
Välittäjätilasto
Dataa ei löytynyt